

EXECUTIVE DIRECTORS

Dr. Wan Kwong Kee, aged 55, is the Chairman of the Company. He has extensive experience in research and development in biotechnology and pharmaceuticals. Dr. Wan obtained his B.Sc.Pharm. and M.Sc.Pharm. degrees from the University of Toronto, Canada in 1970 and 1973 respectively, and obtained his Ph.D. (Pharmacology) from Queen's University in Ontario, Canada in 1982, followed by post-doctoral training in the Receptor Biology Laboratory of Salk Institute in La Jolla, USA and a research fellowship in the Faculty of Medicine at the University of Toronto, Canada from 1982 to 1986. Dr. Wan had worked as a chief pharmacist in a public hospital in Canada during the period from 1973 to 1978. Since 1986, Dr. Wan had been an Assistant Professor in the Faculty of Medicine at the University of Toronto, Canada and the Medical School at Northwestern University in Chicago, USA for approximately five years. In 1991, Dr. Wan joined The Hong Kong University of Science and Technology as a Lecturer and became a university senate member in 1992. During his professorship in the universities, he had conducted extensive research in molecular pharmacology. In 1994, Dr. Wan returned to Canada and had worked as a consultant and scientist in a pharmaceutical company and as a researcher in a public hospital for approximately five years. In 1999, Dr. Wan came back to Hong Kong again and founded a company specializing in the research and development of DNA biotechnology related products, and has since become the President and Chief Scientist of that company. He joined the Company in July 2000.

Mr. Chan Peng Kuan, aged 37, is the Managing Director of the Company. He graduated from University of Canterbury in New Zealand with a Bachelor of Commerce degree and obtained a Master of Applied Finance degree from Macquarie University in Australia. Mr. Chan is a chartered accountant in New Zealand, a member of the Hong Kong Society of Accountants, a senior associate of the Australasian Institute of Banking and Finance and a member of the Hong Kong Securities Institute. Mr. Chan has extensive experience in investment banking, auditing, securities research and direct investments. Prior to joining the Company in August 2000, Mr. Chan was an executive director of an international investment bank, at which he gained extensive experience in initial public offerings, merger and acquisitions, corporate restructuring and financial advisory.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Zhou Haijin, aged 68, was appointed Independent Non-executive Director of the Company on 13 April 2001. He graduated from Suzhou Tung Wu University and was awarded a bachelor degree in Pharmaceuticals. He was formerly the Director of the National Institute for the Control of Pharmaceutical and Biological Products, PRC from 1983 to 1999. Professor Zhou is now a member of the Expert Committee on Biological Standardisation in the World Health Organisation, the Honorary President of National Institute for the Control of Pharmaceutical and Biological Products, PRC and the Honorary President of Chinese Pharmaceutical Association.

Mr. Ng Wai Hung Thomas, aged 37, has been a director of the Company since September 2000. He is a practising solicitor in Hong Kong and a partner in the Hong Kong law firm of Lu, Lai & Li.

ADVISORY BOARD MEMBERS

Dr. Wang Guangji, aged 47, was appointed as a member of the Science Advisory Board of the Company on 11 April 2001. Professor Wang graduated from the China Pharmaceutical University at Nanjing, the PRC in 1977. He obtained his Ph.D in 1993 and post-doctoral training from the University of Otago in New Zealand. Professor Wang is currently the Vice President of the China Pharmaceutical University at Nanjing and a member of the New Drug Evaluation Committee of both the State Drug Administration and Jiangsu Province. Also, he is a professor and the director of the New Drug and Development Centre of China Pharmaceutical University and Pharmacokinetic Research Centre. He is an expert in the pharmacokinetics of chemical drugs, biotechnology derived drugs, traditional Chinese Medicine and sustained release preparations.

Mr. Wang Kaimin, aged 66, was appointed as a member of the Science Advisory Board of the Company on 9 April 2001. Professor Wang graduated from the Department of Pharmacology in drug analysis, Medical College of Beijing University in 1956. He was a pharmacist and researcher at the Institute for the Control of Pharmaceutical and Biological Products formerly in the Ministry of Health, PRC in 1964. He was the Chief Pharmacist and Vice Director of the National Institute for the Control of Pharmaceutical and Biological Products in 1983. At present, he serves as a consultant for that Institute. He is also a member of the Drug Evaluation Committee, Expert Committee of Good Laboratory Practice of the State Drug Administration (SDA) and the Committee on Antibiotics of the Chinese Pharmacopoeia Commission. Professor Wang has published frequently in academic journals and written reports for national and international organizations, including World Health Organization, regarding drug testing and quality control. He is the editor-in-chief of Chinese Pharmaceutical and serves in the editorial board of the Chinese Journal of New Drugs and Chinese Journal of Drug Analysis.

Dr. Xie Yong, graduated from Fudan University, the PRC with a B.Sc and M.Sc in Biology and obtained his Ph.D in Cornell University. Dr. Xie is currently an Associate Professor of Department of Biology of Hong Kong University of Science and Technology. He focuses his research in liver cancer, autoimmune diseases and swine foot-and-mouth viral disease.

Dr. Kwong Chi Wai, Simon, graduated from National Taiwan University and obtained his Ph.D in Chemical and Biochemical Engineering from the University of Maryland. Dr. Kwong has extensive experience in biotechnology and pharmaceuticals and is currently the Deputy Managing Director of the Hong Kong Institute of Biotechnology.

Dr. Chow Wing Cho, graduated from University of Hong Kong with a MBBS degree and obtained the advanced degrees of DCH and MRCP from the UK. Dr. Chow went to private practice in 1986 and became the Paediatrician of the Humphrey & Partners Medical Services Group and he further obtained FHKAM degree in 1996. Dr. Chow is currently the executive director of Humphrey & Partners Medical Services.